Search

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

Analysis of ‘urgent’ cataract referrals from community optometrists in the West of Scotland

As elective cataract services restart post-COVID, how do we establish which patients should be a priority? The authors share their findings from a review of ‘urgent’ referrals received by the ophthalmology department in NHS Greater Glasgow & Clyde. The COVID-19...

Safety and efficacy of a nurse-led intravitreal injection service using an Precivia® injection assist device

Nurse-led intravitreal injections have become of great importance for busy eye units. In this article, the authors present safety data from five years of a nurse-led service with the use of the Precivia® intravitreal injection assist device. Intravitreal injections of...

Uveal melanoma

Uveal melanoma is the most common primary intraocular tumour. However, they are still rare, with an incidence of 2-8 per million [1]. The presence of a choroidal naevus is a risk factor for uveal melanoma [1]. Patients with choroidal lesions...

Are hospital cataract services managing more complex cases?

An audit of referral pathways and case mix in hospital cataract services. Cataract is the leading cause of irreversible blindness worldwide, causing severe visual impairment, particularly within ageing populations [1]. Gradual lens opacification impairs contrast sensitivity, visual acuity and overall...

Intraocular lens technology to deliver enhanced optical performance after cataract refractive surgery

Modern cataract surgery aims to provide patients with the best possible visual outcome with the least dependence on spectacles and minimal or no complications and to treat both cataract and refractive errors with a single procedure. Phacoemulsification is the standard...

Strategies for managing neovascular AMD and DMO in routine clinical care

Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO) illustrate increasing adoption of patient-tailored treatment approaches based on initial diagnosis and regular monitoring of imaging and visual outcomes in routine clinical care. The...

Genetic profiling for personalised healthcare solutions in AMD – an update

Age-related macular degeneration (AMD) is a multifactorial condition influenced by genetics and lifestyle factors (Table 1). This article outlines several recent advances in AMD genetics, as well as evolving therapeutic concepts and established practical measures for the treatment and /...

Advances and developments in medical retina

The author provides an update on late breaking clinical trial results in neovascular age-related macular degeneration (nAMD) and presentations on diabetes management from the American Academy of Ophthalmology Retina Subspecialty Day, held during the Academy’s annual meeting in Chicago, October...

Newer generation IOL platforms designed for high-quality visual performance after cataract surgery

Expanding intraocular lens (IOL) capabilities provide broadening options, ranging from next-generation monofocal IOLs for basic cataract surgery, to specialised premium IOLs for lens-based presbyopia correction and astigmatism correction at the time of cataract surgery. Rod McNeil considers several newer alternative...

Broadening of treatment options for potentially blinding retinal conditions

Rod McNeil provides an update on a promising bispecific antibody recently approved for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) and considers emerging developments in biosimilars to established anti-vascular endothelial growth factor (anti-VEGF) therapies, including...

Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...